FDA Approves Sotyktu for Active Psoriatic Arthritis | Healio

The Food and Drug Administration has approved deucravacitinib, marketed as Sotyktu, for the treatment of adults with active psoriatic arthritis (PsA). This expands the drug’s application beyond its prior approval for moderate-to-severe plaque psoriasis. The approval follows positive results from the POETYK PsA trials, offering a novel oral treatment option for individuals managing both the skin and joint manifestations of this chronic inflammatory condition.

Psoriatic arthritis is a complex disease that combines the symptoms of psoriasis – a skin condition characterized by scaly, red patches – with arthritis, causing joint pain, stiffness, and swelling. It affects an estimated 1.5 million adults in the United States, though prevalence estimates vary. The condition can significantly impact quality of life, and treatment often involves a combination of medications to manage both the skin and joint symptoms.

How Deucravacitinib Works

Deucravacitinib is a selective tyrosine kinase 2 (TYK2) inhibitor. TYK2 is an enzyme involved in the signaling pathways that drive inflammation. By selectively blocking TYK2, the drug aims to reduce the inflammatory response underlying both the skin and joint symptoms of psoriatic arthritis. Unlike some other treatments for PsA that broadly suppress the immune system, deucravacitinib’s targeted approach may offer a more focused effect, potentially minimizing some of the broader side effects associated with more systemic immunosuppression.

Trial Results: POETYK PsA-1 and POETYK PsA-2

The FDA’s decision was based on data from two Phase 3 clinical trials, POETYK PsA-1 and POETYK PsA-2. These trials involved a total of 670 patients with active psoriatic arthritis. In POETYK PsA-1, patients receiving the 6 mg dose of deucravacitinib achieved an ACR20 response – a measure of improvement in arthritis symptoms – in 54.2% of cases, compared to 34.1% in the placebo group (P < .0001). ACR20 signifies at least a 20% improvement in tender joint count, swollen joint count, and patient assessment of pain.

POETYK PsA-2 investigated patients who switched from placebo to active treatment with deucravacitinib at week 16. Results showed that 60.8% of these patients achieved an ACR20 response by week 52. These findings, published in peer-reviewed journals and presented at medical conferences, demonstrate the sustained efficacy of deucravacitinib over a year-long period.

What the Trials Don’t Tell Us

Even as the POETYK trials demonstrate significant efficacy, it’s important to consider their limitations. The trials primarily focused on ACR20 response, a measure of symptomatic improvement. Longer-term data on structural joint damage progression are still needed. The trials did not directly compare deucravacitinib to other commonly used treatments for psoriatic arthritis, such as TNF inhibitors or IL-17 inhibitors. It remains unclear where deucravacitinib fits within the broader treatment landscape.

Expert Perspective

“We welcome the addition of deucravacitinib to our PsA treatment armamentarium,” said Philip J. Mease, MD, of the Swedish Medical Center and the University of Washington. “Sotyktu is an effective oral treatment option which fulfills an unmet require both for patients who prefer an oral and reasonably safe medication early in their treatment course, as well as a new mechanism of action, TYK2 inhibition, to use in patients who have experienced loss of effect or intolerability to a prior immunomodulatory medication.” Dr. Mease’s comments, reported by Healio, highlight the potential of deucravacitinib to address gaps in current treatment options.

Safety Considerations

As with any medication, deucravacitinib carries potential risks and side effects. Clinical trials have reported common adverse events including upper respiratory tract infections, nasopharyngitis (the common cold), and headache. The prescribing information includes warnings about increased risk of infections, including serious infections, due to the drug’s immunosuppressive effects. Patients should discuss potential risks and benefits with their healthcare provider before starting treatment.

What’s Next for Deucravacitinib and PsA Treatment

The FDA approval of deucravacitinib marks a significant step forward in the treatment of psoriatic arthritis. Ongoing research will continue to evaluate the drug’s long-term efficacy and safety, as well as its potential role in combination with other therapies. Further studies are needed to determine the optimal patient selection criteria for deucravacitinib and to compare its effectiveness to other available treatments. The availability of a new oral TYK2 inhibitor provides clinicians and patients with another valuable tool in the fight against this debilitating condition. The U.S. FDA’s decision is likely to prompt similar reviews by regulatory bodies in other countries, potentially expanding access to deucravacitinib globally.

Bristol Myers Squibb, the manufacturer of Sotyktu, has indicated that they will continue to explore the drug’s potential in other immune-mediated diseases, suggesting that this approval may be the first of many for deucravacitinib. Patients interested in learning more about deucravacitinib and whether it might be a suitable treatment option should consult with a qualified rheumatologist.